EICHOR
● Active Not Recruiting
Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis
Condition: Retinitis Pigmentosa · Leber Congenital Amaurosis · Sponsor: Ocugen
About this study
This is a Phase 1/2 Study to Assess the Safety and Efficacy of OCU400 in patients with retinitis pigmentosa associated with NR2E3 and RHO mutations and in patients with LCA due to mutation(s) in CEP290 gene (OCU400-101). To document prospective eye pathology in the above subjects Investigators will also conduct a Natural History Study (OCU400-104)i This is a multicenter study, which will be conducted in two phases and will enroll up to a total of 24 subjects in the OCU400-101 and 100 subjects in the OCU400-104 study.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (7)
| Associated Retina Consultants | Phoenix, Arizona, United States | — |
| Ocugen Site 5 - University of California, San Diego (UCSD) - Shiley Eye Institute | La Jolla, California, United States | — |
| Ocugen Site 3 - Bascom Palmer Eye Institute | Miami, Florida, United States | — |
| Ocugen Site 6 - Emory University | Atlanta, Georgia, United States | — |
| Ocugen Site 2 - Casey Eye Institute - OHSU | Portland, Oregon, United States | — |
| Ocugen Site 8 - Mid Atlantic Retina - Wills Eye Hospital | Philadelphia, Pennsylvania, United States | — |
| Ocugen Site 1 - Retina Foundation of the Southwest | Dallas, Texas, United States | — |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05203939